Recently, a promising clinical antagonist GSK2193874, which possesses high TRPV4 affinity, has been shown to efficiently prevent and treat lung edema in heart failure models and congestive heart failure [62] (Table 2). The gene discussed is TRPV4; the disease is congestive heart failure.